1–3 of 3 results for cost-effective
Economic Impact of Anti-Vascular Endothelial Growth Factor Prior Authorization Process
Ella H Leung, MD
Annual Meeting Talks
2025
Cost-Effectiveness of Aflibercept Monotherapy vs Bevacizumab-First Followed by Switching to Aflibercept if Needed for Diabetic Macular Edema
Mathew W. MacCumber, MD, PhD
2023
Expert Panel: Socioeconomics
Linda A. Lam, MD, MBA, FASRS
Mohsin H. Ali, MD
Hasenin Al-khersan, MD
Miguel A. Busquets, MD, FACS
2024